vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Vital Farms, Inc. (VITL). Click either name above to swap in a different company.
Vital Farms, Inc. is the larger business by last-quarter revenue ($213.6M vs $183.1M, roughly 1.2× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 7.6%, a 5.7% gap on every dollar of revenue. On growth, Vital Farms, Inc. posted the faster year-over-year revenue change (28.7% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-32.1M). Over the past eight quarters, Vital Farms, Inc.'s revenue compounded faster (20.2% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Vital Tomosi Dairy Limited is a dairy processing company in Uganda. The company is a joint venture between Vital Capital Fund, "an impact investing fund primarily focused on Sub-Saharan Africa", and "Tomosi Dairy Farms, a Ugandan producer of dairy products".
AMPH vs VITL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $213.6M |
| Net Profit | $24.4M | $16.3M |
| Gross Margin | 46.8% | 35.8% |
| Operating Margin | 19.4% | 10.0% |
| Net Margin | 13.3% | 7.6% |
| Revenue YoY | -1.8% | 28.7% |
| Net Profit YoY | -35.7% | 54.3% |
| EPS (diluted) | $0.51 | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $213.6M | ||
| Q3 25 | $191.8M | $198.9M | ||
| Q2 25 | $174.4M | $184.8M | ||
| Q1 25 | $170.5M | $162.2M | ||
| Q4 24 | $186.5M | $166.0M | ||
| Q3 24 | $191.2M | $145.0M | ||
| Q2 24 | $182.4M | $147.4M | ||
| Q1 24 | $171.8M | $147.9M |
| Q4 25 | $24.4M | $16.3M | ||
| Q3 25 | $17.4M | $16.4M | ||
| Q2 25 | $31.0M | $16.6M | ||
| Q1 25 | $25.3M | $16.9M | ||
| Q4 24 | $38.0M | $10.6M | ||
| Q3 24 | $40.4M | $7.4M | ||
| Q2 24 | $37.9M | $16.3M | ||
| Q1 24 | $43.2M | $19.0M |
| Q4 25 | 46.8% | 35.8% | ||
| Q3 25 | 51.4% | 37.7% | ||
| Q2 25 | 49.6% | 38.9% | ||
| Q1 25 | 50.0% | 38.5% | ||
| Q4 24 | 46.5% | 36.1% | ||
| Q3 24 | 53.3% | 36.9% | ||
| Q2 24 | 52.2% | 39.1% | ||
| Q1 24 | 52.4% | 39.8% |
| Q4 25 | 19.4% | 10.0% | ||
| Q3 25 | 13.2% | 10.8% | ||
| Q2 25 | 24.2% | 12.9% | ||
| Q1 25 | 21.9% | 13.4% | ||
| Q4 24 | 24.2% | 7.8% | ||
| Q3 24 | 29.8% | 6.4% | ||
| Q2 24 | 30.3% | 11.6% | ||
| Q1 24 | 27.9% | 16.3% |
| Q4 25 | 13.3% | 7.6% | ||
| Q3 25 | 9.0% | 8.3% | ||
| Q2 25 | 17.8% | 9.0% | ||
| Q1 25 | 14.8% | 10.4% | ||
| Q4 24 | 20.4% | 6.4% | ||
| Q3 24 | 21.1% | 5.1% | ||
| Q2 24 | 20.8% | 11.1% | ||
| Q1 24 | 25.1% | 12.9% |
| Q4 25 | $0.51 | $0.35 | ||
| Q3 25 | $0.37 | $0.36 | ||
| Q2 25 | $0.64 | $0.36 | ||
| Q1 25 | $0.51 | $0.37 | ||
| Q4 24 | $0.74 | $0.23 | ||
| Q3 24 | $0.78 | $0.16 | ||
| Q2 24 | $0.73 | $0.36 | ||
| Q1 24 | $0.81 | $0.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $48.8M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $351.3M |
| Total Assets | $1.6B | $518.7M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $48.8M | ||
| Q3 25 | $276.2M | $93.8M | ||
| Q2 25 | $231.8M | $108.2M | ||
| Q1 25 | $236.9M | $156.3M | ||
| Q4 24 | $221.6M | $150.6M | ||
| Q3 24 | $250.5M | $149.5M | ||
| Q2 24 | $217.8M | $133.2M | ||
| Q1 24 | $289.6M | $113.8M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $351.3M | ||
| Q3 25 | $776.7M | $331.2M | ||
| Q2 25 | $757.5M | $309.8M | ||
| Q1 25 | $751.3M | $288.9M | ||
| Q4 24 | $732.3M | $269.3M | ||
| Q3 24 | $727.7M | $253.4M | ||
| Q2 24 | $713.3M | $238.4M | ||
| Q1 24 | $672.4M | $213.3M |
| Q4 25 | $1.6B | $518.7M | ||
| Q3 25 | $1.7B | $481.5M | ||
| Q2 25 | $1.6B | $430.8M | ||
| Q1 25 | $1.6B | $376.9M | ||
| Q4 24 | $1.6B | $359.3M | ||
| Q3 24 | $1.5B | $344.7M | ||
| Q2 24 | $1.5B | $320.5M | ||
| Q1 24 | $1.6B | $300.2M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $5.8M |
| Free Cash FlowOCF − Capex | $24.6M | $-32.1M |
| FCF MarginFCF / Revenue | 13.4% | -15.1% |
| Capex IntensityCapex / Revenue | 4.5% | 17.8% |
| Cash ConversionOCF / Net Profit | 1.35× | 0.35× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $-48.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $5.8M | ||
| Q3 25 | $52.6M | $23.4M | ||
| Q2 25 | $35.6M | $-761.0K | ||
| Q1 25 | $35.1M | $5.3M | ||
| Q4 24 | $29.0M | $14.8M | ||
| Q3 24 | $60.0M | $10.0M | ||
| Q2 24 | $69.1M | $16.1M | ||
| Q1 24 | $55.3M | $23.9M |
| Q4 25 | $24.6M | $-32.1M | ||
| Q3 25 | $47.2M | $-10.6M | ||
| Q2 25 | $25.0M | $-7.6M | ||
| Q1 25 | $24.4M | $2.1M | ||
| Q4 24 | $16.6M | $-3.4M | ||
| Q3 24 | $46.2M | $6.4M | ||
| Q2 24 | $63.1M | $10.5M | ||
| Q1 24 | $46.5M | $22.6M |
| Q4 25 | 13.4% | -15.1% | ||
| Q3 25 | 24.6% | -5.3% | ||
| Q2 25 | 14.3% | -4.1% | ||
| Q1 25 | 14.3% | 1.3% | ||
| Q4 24 | 8.9% | -2.0% | ||
| Q3 24 | 24.1% | 4.4% | ||
| Q2 24 | 34.6% | 7.2% | ||
| Q1 24 | 27.1% | 15.3% |
| Q4 25 | 4.5% | 17.8% | ||
| Q3 25 | 2.8% | 17.1% | ||
| Q2 25 | 6.1% | 3.7% | ||
| Q1 25 | 6.3% | 1.9% | ||
| Q4 24 | 6.7% | 10.9% | ||
| Q3 24 | 7.2% | 2.5% | ||
| Q2 24 | 3.3% | 3.8% | ||
| Q1 24 | 5.1% | 0.9% |
| Q4 25 | 1.35× | 0.35× | ||
| Q3 25 | 3.03× | 1.43× | ||
| Q2 25 | 1.15× | -0.05× | ||
| Q1 25 | 1.39× | 0.31× | ||
| Q4 24 | 0.76× | 1.40× | ||
| Q3 24 | 1.48× | 1.34× | ||
| Q2 24 | 1.82× | 0.99× | ||
| Q1 24 | 1.28× | 1.26× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
VITL
| Eggs And Egg Related Products | $205.8M | 96% |
| Butter And Butter Related Products | $7.7M | 4% |
